A Phase I Study of BKM120 and Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 31 Jul 2019
Price : $35 *
At a glance
- Drugs Buparlisib (Primary) ; Rituximab
- Indications B-cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- 29 Jul 2019 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
- 29 Jul 2019 Planned primary completion date changed from 31 Dec 2018 to 31 Dec 2019.
- 11 Sep 2018 Planned End Date changed from 1 Jun 2018 to 31 Dec 2018.